An Indian company is producing a generic version of Gleevac at the price of US$2,500 (RM8,193) for treating a patient a year, down from US$70,000 (RM229,425).
A local company was granted a compulsory licence to produce a generic version of the drug Sorafenib, which treats kidney and liver cancer for US$140 (RM458) per patient a month, or 30 times cheaper than the original product named Nexavar, which costs US$4,600 (RM15,076).
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
